Summit Therapeutics Inc. (SMMT) Focused on Non-Small Cell Lung Cancer Trial of Ivonescimab

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best cancer stocks to invest in now. On February 23, Summit Therapeutics Inc. (NASDAQ:SMMT) reiterated it is progressing with the development of ivonescimab in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). It’s undertaking multiregional Phase III clinical trials.

In addition, the company has engaged GORTEC, a European Head and Neck Oncology and Radiotherapy Group, to activate clinical sites in a phase III clinical study. The trial is to evaluate ivonescimab monotherapy and ivonescimab in combination with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal.

The US Food and Drug Administration has already accepted the company’s Biologics License Application (BLA) filing for ivonescimab in combination with chemotherapy. The company has also partnered with GSK plc to evaluate ivonescimab in combination with B7-H3 and risvutatug rezetecan in multiple solid tumors.

Meanwhile, Summit Therapeutics exited the fourth quarter of 2025 with $713.4 million in cash and cash equivalents and $412.3 million in short-term investments. Meanwhile, net loss for the full year 2025 widened to $347.2 million, or $0.46 a share, from $179.3 million, or $0.24 a share, in 2024.

Summit Therapeutics Inc. (NASDAQ:SMMT) is a Miami-based biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies to improve patient quality of life and address unmet medical needs. Its lead candidate is ivonescimab, a novel bispecific antibody targeting PD-1 and VEGF for treating solid tumors like non-small cell lung cancer.

While we acknowledge the potential of SMMT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.